Sugi Predict

Sugi Predict / Compounds / SCHEMBL563331

SCHEMBL563331

SCHEMBL563331

O=C(O)c1ccn2c(I)cnc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ MAPT P10636 2/20 0.37
▸ KDM6B O15054 1/20 0.37
▸ TET3 O43151 1/20 0.37
▸ KDM4A O75164 1/20 0.37
▸ BBOX1 O75936 1/20 0.37
▸ KDM5A P29375 1/20 0.37
▸ KDM5C P41229 1/20 0.37
▸ ASPH Q12797 1/20 0.37
▸ KDM4D Q6B0I6 1/20 0.37
▸ TET2 Q6N021 1/20 0.37
▸ ALKBH5 Q6P6C2 1/20 0.37
▸ KDM7A Q6ZMT4 1/20 0.37
▸ KDM8 Q8N371 1/20 0.37
▸ TET1 Q8NFU7 1/20 0.37
▸ EGLN2 Q96KS0 1/20 0.37
▸ FTO Q9C0B1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL557149 0.85 RIPK2 (0.39) KDM4EALDH1A1GAAPKMNPC1
SCHEMBL17350560 0.81 RIPK2 (0.44) KDM4EALDH1A1GAAPKMMAPT
SCHEMBL17350917 0.81 CSF1R (0.41) KDM4EALDH1A1GAAPKMMAPT
SCHEMBL1431796 0.81 PLAU (0.43) KDM4EALDH1A1GAAMAPTKDM5A
SCHEMBL557497 0.81 JMJD6 (0.42) KDM4EALDH1A1GAAPKMMAPT
SCHEMBL9753645 0.81 NPC1 (0.47) KDM4EALDH1A1GAAPKMMAPT
SCHEMBL10174957 0.80 PLAU (0.37) KDM4EALDH1A1GAAPKMNPC1
SCHEMBL24460300 0.80 KDM4E (0.43) KDM4EALDH1A1GAAPKMMAPT
SCHEMBL22598519 0.80 KDM4E (0.43) KDM4EALDH1A1GAAPKMMAPT
SCHEMBL30410251 0.80 KDM4E (0.43) KDM4EALDH1A1GAAPKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114728965-B Pyrido heterocyclic compounds, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-05-28 — — CN disclosed
CN-114728965-A Pyridino-heterocyclic compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2022-07-08 — — CN disclosed
WO-2020216669-A1 PHENYL-SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 — — WO disclosed
US-20200339567-A1 SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 — — US disclosed
US-20200339567-A1 SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 — — US disclosed
WO-2020216669-A1 PHENYL-SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 — — WO disclosed
EP-3700903-A1 SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF Bayer Aktiengesellschaft (DE) 2020-09-02 — — EP disclosed
CN-111225917-A Substituted imidazopyridine amides and uses thereof 拜耳股份公司 2020-06-02 — — CN disclosed
EP-2419428-B1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LTD (GB) 2015-05-13 — — EP disclosed
US-8859582-B2 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2014-10-14 — — US disclosed
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 — — US disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 — — US disclosed
US-20120035152-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2012-02-09 — — US disclosed
US-8076354-B2 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2011-12-13 — — US disclosed
US-8071614-B2 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2011-12-06 — — US disclosed
US-20100331296-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2010-12-30 — — US disclosed
US-20100286113-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY FGFR1, FGFR3, FGFR2 KDM4E 1289/4885ALDH1A1 475/4885GAA 1336/4885
US-20100331296-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, BMX, CDK1 KDM4E 686/4885ALDH1A1 3442/4885GAA 2751/4885
US-20100286113-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, BMX, BTK KDM4E 602/4885ALDH1A1 3554/4885GAA 2458/4885
US-20200339567-A1 SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF GOT2, ABAT, OAT KDM4E 3634/4885ALDH1A1 301/4885GAA 383/4885
US-20120035152-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, BMX, BTK KDM4E 602/4885ALDH1A1 3554/4885GAA 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.